Author

Byong Duk Ye

SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH ACTIVE INFLAMMATORY BOWEL DISEASE: POST-HOC ANALYSIS OF PRE/POST SWITCH OUTCOMES FROM A MULTICENTRE, RANDOMISED CONTROLLED PIVOTAL TRIAL
SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH ACTIVE INFLAMMATORY BOWEL DISEASE: POST-HOC ANALYSIS OF PRE/POST SWITCH OUTCOMES FROM A MULTICENTRE, RANDOMISED CONTROLLED PIVOTAL TRIAL

Byong Duk Ye  et al.

COMPARISON OF COMBINATION SUBCUTANEOUS INFLIXIMAB AND AN IMMUNOMODULATOR VERSUS SUBCUTANEOUS INFLIXIMAB MONOTHERAPY: POST-HOC ANALYSIS OF A RANDOMISED CLINICAL TRIAL
COMPARISON OF COMBINATION SUBCUTANEOUS INFLIXIMAB AND AN IMMUNOMODULATOR VERSUS SUBCUTANEOUS INFLIXIMAB MONOTHERAPY: POST-HOC ANALYSIS OF A RANDOMISED CLINICAL TRIAL

Byong Duk Ye  et al.

REAL-LIFE EFFECTIVENESS AND SAFETY OF USTEKINUMAB INDUCTION THERAPY FOR KOREAN PATIENTS WITH CROHN’S DISEASE: A KASID PROSPECTIVE MULTICENTER STUDY
REAL-LIFE EFFECTIVENESS AND SAFETY OF USTEKINUMAB INDUCTION THERAPY FOR KOREAN PATIENTS WITH CROHN’S DISEASE: A KASID PROSPECTIVE MULTICENTER STUDY

Byong Duk Ye  et al.

DEVELOPMENT OF A ‘NORMAL LIFE INDEX’ (NLI) FOR PATIENTS WITH IBD: ITEM SELECTION THROUGH A WORLD-WIDE PATIENT-CENTRED APPROACH
DEVELOPMENT OF A ‘NORMAL LIFE INDEX’ (NLI) FOR PATIENTS WITH IBD: ITEM SELECTION THROUGH A WORLD-WIDE PATIENT-CENTRED APPROACH

Byong Duk Ye  et al.

DIFFERENCES IN DIRECT HEALTHCARE COST UTILIZATION IN THE FIRST YEAR OF IBD DIAGNOSIS: A BINATIONAL STUDY
DIFFERENCES IN DIRECT HEALTHCARE COST UTILIZATION IN THE FIRST YEAR OF IBD DIAGNOSIS: A BINATIONAL STUDY

Byong Duk Ye  et al.

Item 1 - 5 / 5
1